Nymox Pharmaceutical (NYMX) Stock Price, News & Analysis

Company Overview

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.19 to $0.47
• 52-Week Range: N/A
• Volume: 932,700 shs
• Average Volume: 94,622 shs
• Market Capitalization: $18.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NYMX Stock Analysis - Frequently Asked Questions

How were Nymox Pharmaceutical's earnings last quarter?

Nymox Pharmaceutical Co. (NASDAQ:NYMX) posted its quarterly earnings results on Friday, November, 14th. The biopharmaceutical company reported ($0.02) EPS for the quarter. The biopharmaceutical company earned $0.08 million during the quarter.

What other stocks do shareholders of Nymox Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), Idera Pharmaceuticals (IDRA), MEI Pharma (MEIP), Biocept (BIOC), TherapeuticsMD (TXMD) and CTI BioPharma (CTIC).

Company Calendar

• Last Earnings: 11/14/2014
• Today: 4/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: N/A
• Current Symbol: NASDAQ:NYMX
• CIK: 1018735
• Web: www.nymox.com
• Phone: (800) 936-9669
• Fax: 514-332-2227
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-6,580,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,589.50%
• Return on Assets: -117.25%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.19
• Quick Ratio: 0.19

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.01) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 90,510,000
• Free Float: 41,637,000
• Market Cap: $18.10 million
• Optionable: Optionable
• Beta: 0.64